Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Ed Schuuring, Senior Clinical Scientist in Molecular Pathology and Professor of Molecular Oncology in the Department of ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

Results were presented at the 2023 European Society for Medical Oncology (ESMO) Congress and published in the New England Journal of Medicine. The approval follows the December 2023 and August ...